Vestmark Advisory Solutions’s Sarepta Therapeutics SRPT Stock Holding History

Vestmark Advisory Solutions’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,858	Closed	-$327K	–	811
2023 Q2	$327K	Hold	2,858	–	–	0.01%	691
2023 Q1	$394K	Sell	2,858 -30	-1%	-$3.89K	0.02%	626
2022 Q4	$374K	Sell	2,888 -545	-16%	-$63.2K	0.02%	626
2022 Q3	$379K	Sell	3,433 -1,374	-29%	-$138K	0.02%	602
2022 Q2	$360K	Sell	4,807 -1,163	-19%	-$85.6K	0.02%	620
2022 Q1	$466K	Sell	5,970 -969	-14%	-$74.2K	0.03%	560
2021 Q4	$625K	Hold	6,939	–	–	0.04%	472
2021 Q3	$642K	Buy	6,939 +577	+9%	+$44.4K	0.04%	431
2021 Q2	$495K	Buy	6,362 +390	+7%	+$29.6K	0.04%	479
2021 Q1	$445K	Buy	+5,972	New	+$551K	0.04%	470

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vestmark Advisory Solutions's SRPT Position: Q3 2023 in Review

Vestmark Advisory Solutions sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 2,858 shares — an estimated $327K sold.

Vestmark Advisory Solutions first reported a position in SRPT in Q1 2021 and held it in 10 quarters. The position peaked at $642K in Q3 2021. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

Vestmark Advisory Solutions reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
Vestmark Advisory Solutions sold 2,858 Sarepta Therapeutics shares in Q3 2023, an estimated $327K.
Vestmark Advisory Solutions first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 10 quarters.
Vestmark Advisory Solutions's Sarepta Therapeutics position peaked at $642K in Q3 2021.
394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Vestmark Advisory Solutions's 13F filing for Q3 2023, filed 6 Nov 2023.